# Acadia Healthcare Company Inc. (ACAD) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ACAD/thesis · /stocks/ACAD/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: ACAD
company: Acadia Healthcare Company, Inc.
step: 04
title: Financial Quality & Adversarial Research Sweep
created: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Research Sweep: ACAD

#### 1. Statement Quality Adjustments

##### Income Statement Adjustments

Acadia's GAAP net income is distorted by several significant non-recurring or non-cash items. The following adjustments normalize the picture: [S1][S2]

| Item | FY2024 | FY2025 | Classification |
|------|--------|--------|----------------|
| GAAP Net Income | $255.6M | ($1,102.8M) | — |
| (+) Goodwill Impairment | $0 | $996.2M | Non-cash, Non-recurring |
| (+) Securities Settlement | ~$0 | ~$179M | Cash but non-recurring |
| (+) Legal investigation charges | ~$135M | ~$135M | Cash; elevated vs. steady-state |
| (+) D&A | $149.6M | $189.2M | Non-cash |
| (+) SBC | $37.1M | $31.7M | Non-cash |
| (+) Other adjustments (est.) | ~$5M | ~$5M | Various |
| ≈ **Adjusted EBITDA** | **~$572M** | **$608.9M** | Clean operational metric |

**Judgment [J]:** FY2025 GAAP loss of $1.1B is primarily non-cash (goodwill impairment) and event-driven (securities settlement). The underlying business generated ~$609M Adj. EBITDA — roughly flat-to-growing from FY2024. The key question is whether legal charges normalize meaningfully below $135M/yr as investigations resolve.

##### Cash Flow Adjustments

Operating cash flow is understated relative to true operating performance due to large cash legal payments: [S1]

| Item | FY2024 | FY2025 |
|------|--------|--------|
| Reported OCF | $129.7M | $131.9M |
| (+) Cash legal payments (est.) | ~$135M | ~$135M |
| = Adjusted OCF | ~$265M | ~$267M |

**Note:** Even adjusted, OCF is well below Adj. EBITDA (~$609M) due to working capital expansion (A/R growing as revenue scales), interest payments, and taxes.

##### Balance Sheet Quality

**Goodwill:** $1,296M (post-impairment) vs. $2,265M at FY2024 — the $996M write-down reflects management's acknowledgment that prior acquisition/de novo values were overstated. [S1]

**Goodwill/Total Assets ratio:** 23.5% (FY2025) — significant but manageable. Intangibles represent the cost of the company's growth-by-acquisition history.

**Accounts Receivable:** $440.6M — DSO ~49 days — normal for behavioral health where Medicaid/Medicare pay in 30-45 days but commercial claims can take longer. Allowance for doubtful accounts should be reviewed. [S1]

#### 2. Adversarial Research Sweep

##### Short-Seller and Investigative Reports

No specific short-seller report identifying ACAD/ACHC as a primary target found in web research as of 2026-05-27. However, the DOJ/SEC investigation itself effectively serves as the "bear case" investigation:

##### Regulatory/Legal Actions [S3][S4]

**Timeline of Legal/Regulatory Actions:**

| Date | Action | Amount | Status |
|------|--------|--------|--------|
| 2014-2017 | Alleged Medicare/Medicaid/TRICARE billing fraud (unnecessary inpatient BH services) | — | Underlying period |
| 2017 | OIG/DOJ investigation commenced | — | Triggered investigation |
| Sep 2024 | Civil settlement of OIG/DOJ whistleblower case | $19.85M | Resolved (no admission) |
| 2023-2024 | Securities class action lawsuit | — | Ongoing |
| Nov 2025 | Securities class action settlement accrued | $179M | Pending finalization |
| 2025 | DOJ Criminal Division investigation ongoing | Unknown | Active |
| 2025 | SEC investigation ongoing | Unknown | Active |
| May 2026 | Jury verdict: $105M damages to Acadia entity | Unknown context | Recent |

**Assessment:** The DOJ Criminal Division investigation is the dominant tail risk. Criminal behavioral health fraud prosecutions have resulted in settlements of $500M-$2B+ for large operators. If charges are brought, the company could face:
- Criminal fines
- Corporate integrity agreement (CIA) requiring costly compliance programs
- Potential exclusion from Medicare/Medicaid (extreme scenario — existential)

**Probability assessment [J]:** Medicare/Medicaid exclusion is very low probability given the company's scale (would harm patients); a CIA + civil settlement is more likely. Settlement magnitude is uncertain but $200-500M range is plausible given the scope of the investigation.

##### Operational Risk Indicators

**Facility closure announcement (Oct 2025):** Closing 5 underperforming facilities; laying off 400 employees. [S5]
- This is a positive signal (pruning bad assets) but also indicates the prior expansion was undisciplined
- Management acknowledged de novo startup losses have been higher than planned

**Medicaid dependency and regulatory risk:**
- NY Medicaid policy: $25-30M EBITDA headwind in 2026
- Federal Medicaid: DOGE-related federal budget discussions create policy uncertainty
- Pattern: State Medicaid rate changes are the most frequent source of earnings volatility for ACAD

##### Accounting Quality Flags

| Flag | Severity | Notes |
|------|---------|-------|
| Large goodwill ($1.3B, 23% of assets) | Medium | Post-impairment; future impairment risk remains |
| Negative free cash flow (FY2024-2025) | High | CapEx-driven; expected to reverse 2026; must confirm |
| Legal charges embedded in OCF | Medium | Obscures true operating cash conversion |
| Adjusted EBITDA excludes SBC | Low | Standard for sector; $32M SBC is ~5% of Adj. EBITDA |
| Revenue recognition (ASC 606) | Low | Standard patient service revenue; no concerning flags |

#### 3. Financial Quality Summary

**Overall Financial Quality: MEDIUM**

The underlying revenue and Adj. EBITDA trajectory are solid — $3.3B revenue growing mid-single digits, ~18% Adj. EBITDA margin, strong operational scale. The quality concerns are:
1. Legal/regulatory overhang (DOJ Criminal + SEC) — binary tail risk
2. FCF deeply negative from CapEx cycle; normalization expected in 2026 but not yet demonstrated
3. Balance sheet leverage (4.1x net debt/Adj. EBITDA) limits financial flexibility
4. Management credibility damage from prior guidance misses and legal failings

#### Source Index

| ID | Source |
|----|--------|
| S1 | SEC XBRL CIK0001520697; 8-K FY2025 earnings press release |
| S2 | Company 10-K FY2025 (filed 2026-02-27) |
| S3 | Web search: Acadia Healthcare DOJ settlement (bhbusiness.com Sep 2024) |
| S4 | Web search: ACHC securities settlement $179M (bhbusiness.com Nov 2025); jury verdict May 2026 |
| S5 | Web search: Acadia Healthcare facility closures, layoffs Oct 2025 (bhbusiness.com) |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ACAD/fundamental

## Navigation

- Overview: /stocks/ACAD
- Financials (this page): /stocks/ACAD/financials
- Thesis: /stocks/ACAD/thesis
- Investment Memo: /stocks/ACAD/memo
- Coverage universe: /stocks